23 March 2018
New Clinical Step for a Drug Candidate from Acasti Pharma
Acasti Pharma has completed a new step in phase 3 of the clinical studies on its drug candidate CaPre: The company announced that a first patient – out of a total of 500 – was randomly selected.
CaPre, an omega-3 phospholipid derived from krill oil, is used in the treatment of severe hypertriglyceridemia, a disease that causes high blood triglyceride levels and may increase the risk of coronary diseases and pancreatitis.
Results from the TRILOGY clinical program on the safety and effectiveness of the drug candidate are expected for the end of 2019.
The first two phases of clinical studies were conclusive, and the medication could soon be used to help numerous people suffering from severe hypertriglyceridemia, estimated at 3 to 4 million people in the United States, according to the American Heart Association.
» Read full article for more details
Source : Acasti PharmaBack to the news